Department of Oral Cell Biology, Academic Centre for Dentistry Amsterdam (ACTA), Vrije Universiteit Amsterdam and University of Amsterdam, Amsterdam, The Netherlands.
Department of Second Dental Center, Shanghai Jiao Tong University School of Medicine, College of Stomatology, Shanghai Jiao Tong University, National Centre for Stomatology, National Clinical Research Center for Oral Diseases, Shanghai Key Laboratory of Stomatology, Shanghai Research Institute of Stomatology, Shanghai, China.
Int J Implant Dent. 2024 Oct 30;10(1):47. doi: 10.1186/s40729-024-00567-6.
Although bone morphogenetic protein-2 (BMP-2) possesses potent osteoinductivity, there have been some concerns on the safety of BMP-2 and BMP-2-incorporated bone substitutes used for bone formation. On the other hand, BMP-2-loaded calcium phosphate cement (BMP-2@CPC) has been developed and used for bone regeneration in oral implantology. Therefore, this study aims to investigate this product's biocompatibility and clinical safety after being used in maxillofacial surgery.
A rat model was employed to assess the osteoinduction and biocompatibility of BMP-2@CPC. Further, a retrospective investigation was carried out: 110 patients who received BMP-2@CPC treatment after their maxillofacial surgery were recruited to describe relative adverse events.
In vivo, BMP-2@CPC showed a significantly higher mean bone volume density and osteoblasts volume density (15 ± 2% and 3 ± 1%)than those of the CPC group (p < 0.05) after being implanted in the dorsal area of rats. Regarding biocompatibility, the mean fibrous tissue volume density was significantly lower in the BMP-2@CPC group (20 ± 5% compared to 31 ± 6%, p = 0.026). The retrospective clinical study showed that only five mild/moderate adverse events were identified in four patients based on the medical records of 110 patients, including swelling, bony mass, and wound dehiscence. This adverse event occurrence was not affected by gender, age, the dose of filled materials, and operations in the study (p > 0.05).
BMP-2-loaded CPC has osteoinductivity and more promising biocompatibility than pure CPC. However, its degradation is slower than CPC. The safety of BMP-2-loaded CPC with 0.5 or 1 mg BMP-2 is promising in oral maxillofacial surgery.
This study confirmed the promising safety of this BMP-2 incorporated CPC used in dental clinical practice, which can promote its reassuring application for dental implant placement in bone insufficient areas.
尽管骨形态发生蛋白-2(BMP-2)具有很强的成骨诱导作用,但人们对 BMP-2 的安全性以及用于骨形成的 BMP-2 掺入骨替代物仍存在一些担忧。另一方面,已开发并用于口腔种植学中的负载 BMP-2 的磷酸钙水泥(BMP-2@CPC)。因此,本研究旨在研究该产品在颌面外科手术后的生物相容性和临床安全性。
采用大鼠模型评估 BMP-2@CPC 的成骨诱导作用和生物相容性。此外,进行了回顾性调查:共招募了 110 名接受 BMP-2@CPC 治疗的颌面外科手术后患者,以描述相关不良事件。
体内,BMP-2@CPC 在植入大鼠背部后,其平均骨体积密度和成骨细胞体积密度(15±2%和 3±1%)明显高于 CPC 组(p<0.05)。关于生物相容性,BMP-2@CPC 组的平均纤维组织体积密度明显较低(20±5%比 31±6%,p=0.026)。回顾性临床研究显示,根据 110 名患者的病历,仅在 4 名患者中发现 5 例轻度/中度不良事件,包括肿胀、骨块和伤口裂开。研究中,不良事件的发生不受性别、年龄、填充材料剂量和手术的影响(p>0.05)。
负载 BMP-2 的 CPC 具有成骨诱导作用和比纯 CPC 更有前景的生物相容性,但降解速度比 CPC 慢。在口腔颌面外科中,0.5 或 1mg BMP-2 负载的 BMP-2 掺入 CPC 是安全的。
本研究证实了负载 BMP-2 的 CPC 在牙科临床实践中具有良好的安全性,这可以使其在骨量不足区域进行牙种植体植入时更加放心地应用。